Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report observed hair regrowth following the treatment of alopecia universalis and atopic dermatitis with tofacitinib, a JAK inhibitor.

This perspective reviews enzyme-instructed self-assembly (EISA) as a conceptual framework for supramolecular chemical biology, emphasizing its innovative role in developing adaptive biomaterials and synthetic cellular machines without providing new experimental results.

In this case report, a 55-year-old woman developed alopecia areata approximately one year into her treatment with upadacitinib for atopic dermatitis, raising questions about a potential drug-induced link that has not been reported before.

In this case report, researchers observed that two sisters with congenital immune disorders experienced partial hair regrowth while receiving tofacitinib for severe alopecia areata, highlighting the need for careful clinical and laboratory monitoring due to potential infection risks associated with JAK inhibitor therapy.

This study observed that Icariside II, an extract from Epimedium brevicornu Maxim, can inhibit the growth of gastric cancer in cell lines and mouse models by promoting apoptosis and suppressing the Wnt/β-catenin signaling pathway, with minimal toxicity to normal gastric cells.

This single observational study reported that a combination of a morning Detox Drink regimen and Malasana yoga practice improved symptoms of chronic constipation in a 37-year-old woman over seven days.

This case study reports that a 15-year-old male with multiple autoimmune conditions showed significant improvement in skin and gastrointestinal symptoms, along with hair regrowth, after 16 weeks of treatment with the JAK-1 inhibitor upadacitinib, demonstrating its potential in managing complex autoimmune disorders.

This review summarized the latest knowledge suggesting that Janus kinase inhibitors may have therapeutic potential for treating skin diseases like atopic dermatitis and psoriasis, especially when conventional therapies do not work.

This conference abstract outlines topics discussed at the International Conference of the Islamic Medical Association of North America and reports no new results.

In this case report, researchers observed that a 35-year-old male with alopecia universalis achieved full regrowth of scalp, eyebrow, and facial hair with oral upadacitinib treatment after previous therapies failed to provide lasting relief.

This study reported that a combination of Myo-inositol and D-chiro-Inositol improved clinical and laboratory parameters in teenage girls with PCOS compared to a placebo.

This case study reported that Ayurvedic treatment using Pracchana and Bibhitaki Lepa significantly improved symptoms of alopecia areata in a 41-year-old woman, reducing patch size and hair fall.

This case report describes an 87-year-old woman diagnosed with type 3 autoimmune polyendocrine syndrome, highlighting the importance of recognizing and managing coexisting autoimmune conditions.

Upadacitinib effectively treated severe hair loss in a child.

In this study, the researchers used molecular docking to identify Erythrabyssin II from Erythrina subumbrans as a potential candidate for anti-alopecia treatment, comparable to minoxidil, suggesting clinical trials are needed to evaluate its pharmacological effects.

This study on feather pattern formation in chicken skin found that inhibiting gap junctional intercellular communication can lead to the emergence of new feather buds in specific spatial patterns, suggesting that GJIC may facilitate Turing-type periodic patterning by propagating inhibitory signals over long distances.

This study evaluated 386 patients with inborn errors of immunity and found that over half exhibited cutaneous, ocular, or hair manifestations, with bacterial skin infections and eczema being particularly prevalent. These findings may aid early diagnosis, especially in pediatric cases.

In this case report, a 57-year-old man with severe atopic dermatitis, vitiligo, and alopecia areata showed rapid and significant improvement after treatment with the JAK1 inhibitor upadacitinib, suggesting its potential as an effective monotherapy for these co-existing conditions when conventional therapies fail.

This study investigated whether the iodine concentration in hair correlates with spontaneous tinea capitis cure at puberty but does not report new clinical findings.

In this report, a clinical case demonstrated complete hair regrowth in a 29-year-old male with recurrent alopecia areata following five months of Ayurvedic treatments, including Virechan therapy, Shamana Chikitsa, and leech therapy, with no adverse effects reported.

Adalimumab significantly improves quality of life for patients with moderate to severe hidradenitis suppurativa.

This abstract describes the 2001 meeting of the Italian Society of Hair Restoration in Siracusa but reports no new research findings.

This case study reports that an infant with maple syrup urine disease developed acrodermatitis dysmetabolica due to low isoleucine levels, and increasing the isoleucine dose improved the condition.

In this case study, treatment with the selective JAK1 inhibitor upadacitinib significantly improved symptoms in a patient with refractory alopecia areata, vitiligo, ankylosing spondylitis, and allergic asthma-nasal syndrome, though a transient liver function abnormality was noted.

In this case study, a patient with refractory oral lichen planus experienced marked improvement within one month of daily treatment with baricitinib, contributing to the evidence supporting the use of JAK inhibitors for lichen planus.

In this study, patients with specific skin and scalp conditions, including eczematous lesions, showed significant improvement after two weeks of oral tofacitinib treatment, as evidenced by changes in the trunk lesions.